Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE CLL-1: Epcoritamab in R/R CLL and Richter's Syndrome
NCT04623541Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2020
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 2 trial of epcoritamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's syndrome (RS), sponsored by Genmab. Started Nov 2020; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT04623541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623541.